These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 22555092)

  • 1. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients.
    Dietrich D; Hasinger O; Liebenberg V; Field JK; Kristiansen G; Soltermann A
    Diagn Mol Pathol; 2012 Jun; 21(2):93-104. PubMed ID: 22555092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
    Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW
    Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
    Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
    Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates.
    Dietrich D; Kneip C; Raji O; Liloglou T; Seegebarth A; Schlegel T; Flemming N; Rausch S; Distler J; Fleischhacker M; Schmidt B; Giles T; Walshaw M; Warburton C; Liebenberg V; Field JK
    Int J Oncol; 2012 Mar; 40(3):825-32. PubMed ID: 22108652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
    Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
    Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
    Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
    Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients.
    Göbel G; Auer D; Gaugg I; Schneitter A; Lesche R; Müller-Holzner E; Marth C; Daxenbichler G
    Breast Cancer Res Treat; 2011 Nov; 130(1):109-17. PubMed ID: 21221769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer.
    Lin X; Gu J; Lu C; Spitz MR; Wu X
    Clin Cancer Res; 2006 Oct; 12(19):5720-5. PubMed ID: 17020976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
    Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
    Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients.
    Son JW; Jeong KJ; Jean WS; Park SY; Jheon S; Cho HM; Park CG; Lee HY; Kang J
    Cancer Lett; 2011 Dec; 311(1):29-37. PubMed ID: 21757291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
    Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
    Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylated DLX4 Predicts Response to Pathologic Stage I Non-Small Cell Lung Cancer Resection.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Ohdan H; Okada M
    Ann Thorac Surg; 2015 May; 99(5):1746-54. PubMed ID: 25825198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
    Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
    Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.
    Tsai MF; Wang CC; Chang GC; Chen CY; Chen HY; Cheng CL; Yang YP; Wu CY; Shih FY; Liu CC; Lin HP; Jou YS; Lin SC; Lin CW; Chen WJ; Chan WK; Chen JJ; Yang PC
    J Natl Cancer Inst; 2006 Jun; 98(12):825-38. PubMed ID: 16788156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [RUNX3 promoter hypermethylation and prognosis of early surgically resected non-small cell lung cancers].
    Tang Y; Wu F; Hu C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Jul; 36(7):650-4. PubMed ID: 21873791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery.
    Dai CH; Li J; Shi SB; Yu LC; Ge LP; Chen P
    Jpn J Clin Oncol; 2010 Apr; 40(4):327-35. PubMed ID: 20056675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non-small cell lung cancer.
    Harada H; Miyamoto K; Yamashita Y; Nakano K; Taniyama K; Miyata Y; Ohdan H; Okada M
    Cancer; 2013 Feb; 119(4):792-8. PubMed ID: 23335114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.